MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
More news: Research
Written by / Agency / Source: Bruker Corporation
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Bruker and Champalimaud Foundation Announce Collaboration to Develop Novel Ultra-High Field 18 Tesla Preclinical MRI System and Applications - World’s highest field preclinical MRI will be used for oncology and neuroscience research - FChampalimaud.org / Bruker.com
Bruker and Champalimaud Foundation Announce Collaboration to Develop Novel Ultra-High Field 18 Tesla Preclinical MRI System and Applications

 

NewswireToday - /newswire/ - Montréal, Québec, Canada, 2019/05/13 - World’s highest field preclinical MRI will be used for oncology and neuroscience research - FChampalimaud.org / Bruker.com. NASDAQ: BRKR

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Research Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

At the Annual Meeting of the International Society for Magnetic Resonance in Medicine (ISMRM), Bruker today announced an agreement to develop the world’s first 18 Tesla 11 cm bore, preclinical ultra-high field (UHF) magnetic resonance imaging (MRI) system and its clinical research applications in collaboration with the Champalimaud Foundation. This novel and unique system is expected to enable Champalimaud researchers to advance translational cancer and neuroscience research with UHF MRI and magnetic resonance spectroscopic imaging.

The 18T MRI is expected to be installed in late 2021 in the Neuroplasticity and Neural Activity laboratory under Dr. Noam Shemesh, with the goal to develop novel contrast mechanisms in MRI and spectroscopic imaging. The Champalimaud Foundation focuses its research on neuroscience and oncology, and the 18T system will advance the Foundation’s in vivo research into cancer, metastasis and pre-metastatic niches (PMNs) in multiple cancer models. It will also advance research into brain plasticity and activity in normal and neurodegenerative disease models.

The ultimate goal of the Champalimaud Foundation is to improve clinical outcomes. The preclinical 18T MRI will facilitate the discovery of new spatially-resolved contrast mechanisms for elucidating biological function, and it will enhance temporal resolution to access additional information on brain dynamics.

Dr. Noam Shemesh, Principal Investigator at the Champalimaud Foundation, stated: “We are very excited to explore the full potential of the 18T MRI system, and to advance our understanding of biological mechanisms underlying healthy and diseased conditions. We intend to harness the 18T ultra-high field and enhanced sensitivity to facilitate investigations into microstructure and metabolism dynamics in the brain, as well as in cancer, highlighting MRI as a tool for answering fundamental questions in biology, and not ‘just’ as a powerful diagnostic tool. We have a well-established, long-lasting collaboration with Bruker, and we are fully confident in the new science that will emerge from this project.”

Dr. Wulf-Ingo Jung, President of Bruker’s Preclinical Imaging division, added: “We are extremely pleased to partner with the Champalimaud Foundation to collaborate on unique, enabling research tools to advance scientific research in both neuroscience and oncology. This exciting UHF MRI partnership will be a demonstration of what can be achieved in collaboration with a leading medical research institution.”

About Champalimaud Foundation (Fundação Champalimaud)

The Champalimaud Foundation in Lisbon, Portugal (fchampalimaud.org), is a leader and promoter of knowledge, working to develop innovative projects and find solutions to the pressing health problems around the globe. Professor Noam Shemesh’s future research using the 18 Tesla system hopes to answer existing biological questions, such as the exploration of early biomarkers for cancer, whilst creating profound new questions for the future.

About Bruker Corporation

Bruker (bruker.com) is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy and nanoanalysis, and in industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research and clinical microbiology.

Investor Contact: Pamela Clark - Bruker Investor Relations
T: +1 978-663-3660 x1479 - E: investor.relations[.]bruker.com.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Research Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Bruker Corporation

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Research articles,
CATCH Visitors via Your Competitors Announcements!


Bruker and Champalimaud Foundation Announce Collaboration to Develop Novel Ultra-High Field 18 Tesla Preclinical MRI System and Applications

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Thorsten Thiel, Ph.D. - Bruker.com 
+49(721) 5161 6500 thorsten.thiel[.]bruker.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Bruker Corporation securities in any jurisdiction including any other companies listed or named in this release.

Research via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Bruker Corporation / Company Profile


Read Research Most Recent Related Newswires:

Innovative MYRRHA Research Reactor Starting to Take Shape
BASF and BNP Brinkmann Acting as Project Partners to Support Current DLR Research on the Future of Mobility
BASF and CTIBiotech to Develop First 3D Bioprinted Human Reconstructed Skin Including Immune Macrophages
Bruker Announces Acquisition of Preclinical and Molecular Imaging Research Software Provider PMOD Technologies, LLC
Rohde & Schwarz and Martin Luther University Halle-Wittenberg Establish Research Partnership
Biomedical Software Startup BostonGene Secures M in Series A Financing from NEC
Imec, UZ Leuven, KU Leuven, The Ghent University, Agilent, Western Digital and BlueBee Develop Unique Hybrid Cloud Platform
Digital Revolution - Naval Group, B<>com’s New Industrial Investor
Bruker and the Translational Metabolic Lab At Radboud University Announce the Establishment of A Joint Center of Excellence for Translational Omics
Rohde & Schwarz and Helmut Schmidt University Hamburg Conduct Joint Research
Imec Researcher Receives ERC Advanced Grant to Develop Ultra-bright Thin-film Light Sources and Lasers
DSM Sets Science-based Reduction Targets for Emissions
Novel Nanomaterial Promises Improvements in Batteries and Many More Sustainable Applications
OnePlanet, a New Dutch Innovation Center for Food, Health and Agricultural Technology
Sequential Infiltration Synthesis (SIS) Significantly Improves EUV Patterning

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Limelon Advertising, Co.

Visit  JobsWare.com





 
  ©2019 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)